Jerini Reports Financial Results for First Nine Months of 2008

| Source: Jerini AG

BERLIN, Nov. 14, 2008 (GLOBE NEWSWIRE) -- Jerini AG (FSE:JI4) reported financial results according to International Financial Reporting Standards (IFRS) for the first nine months ended September 30, 2008.

Total revenues for the nine-month period ended September 30, 2008, decreased by 51.6 percent to EUR 7.8 million (prior year period: EUR 16.2 million). Revenues from collaboration agreements decreased to EUR 3.3 million (prior year period: EUR 13.0 million). Revenues from product sales amounted to EUR 4.5 million (prior year period: EUR 3.2 million) and were mainly generated by Jerini's wholly-owned subsidiary JPT Peptide Technologies GmbH, whose revenues increased to EUR 4.3 million (prior year period: EUR 3.2 million). In the third quarter 2008, for the first time Jerini AG generated revenues from product sales in Germany and France amounting to EUR 0.2 million (prior year period: EUR 0.0 million) following granting of a marketing authorization for Firazyr(r) by the European Commission. Cash and cash equivalents as of September 30, 2008, amounted to EUR 19.4 million.

Research and development expenses decreased in the first nine months of 2008 to EUR 18.5 million (prior year period: EUR 20.3 million). General and administrative expenses increased to EUR 15.1 million (prior year period: EUR 7.0 million). Marketing and sales expenses increased to EUR 7.9 million (prior year period: EUR 4.8 million). Loss from operations before tax and finance cost (EBIT) increased to EUR 35.4 million (prior year period: EUR 17.2 million). Net loss for the nine-month period ended September 30, 2008 amounted to EUR 34.2 million (EUR 15.5 million for the first nine months of 2007). Loss per share for this period amounted to EUR 0.63 (prior year period: EUR 0.29).

Net cash burn for the first nine months of 2008 amounted to EUR 41.3 million (prior year period: EUR 15.3 million). Net cash burn is calculated by the addition of cash used in operating activities (EUR 36.4 million) and cash used in investing activities (EUR 4.9 million), as disclosed in the unaudited consolidated cash-flow statements for the nine-month period ended September 30, 2008.


In April 2008, Jerini received a Not Approvable Letter from the US Food and Drug Administration (FDA) in response to the company's request for marketing authorization of Icatibant for the treatment of hereditary angioedema (HAE) in the US. Jerini plans to file a complete response to the FDA's letter by the end of the year in which it will address the issues raised by the FDA and specifically outline how the Phase III data demonstrate the safety and efficacy of Icatibant for the treatment of HAE.

Jerini's roll-out activities for Firazyr(r) in Europe are ongoing, and commercial and preapproval sales have begun in France, Germany, Belgium, and the UK. Product launch is expected in Austria and Luxemburg by the end of the year. In addition, Jerini expects that Firazyr(r) will be available in the next two months in Italy, Spain, Norway, Sweden, Denmark, Finland, and Portugal via paid named patient programs, while pricing and reimbursement procedures continue.

About Jerini AG

Jerini is a pharmaceutical company based in Berlin, Germany, focusing on the discovery, development, and commercialization of novel peptide-based drugs. The company pursues disease indications that have limited or no treatment options and has built a drug pipeline composed of its own programs, as well as others in collaboration with established partners. Jerini has been granted marketing authorization by the European Commission for Firazyr(r) in the treatment of acute attacks of hereditary angioedema. Jerini has also established several in-house development programs, which address indications within the therapeutic areas of ophthalmology, oncology, and inflammatory disease. On July 3, 2008, Jerini and Shire Limited's German wholly-owned indirect subsidiary Shire Deutschland Investments GmbH ("Shire") entered into a business combination agreement regarding a strategic partnership. Jerini is now a subsidiary of Shire plc and a member of the Shire group of companies. Shire currently holds more than 93 percent of Jerini's shares.

Jerini AG
Stacy Wiedenmann
Director Investor Relations & Corporate Communications
Fax +49-30-97893-105

Invalidenstr. 130
10115 Berlin